BioPharma Credit Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO

BioPharma Credit has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Rolf Kristian Berndtson Soderstrom	Independent Non-Executive Director	3.6yrs	US$82.29k	0.016% $ 174.8k
Harry Hyman	Independent Non-Executive Chairman	7.2yrs	US$116.35k	0.0084% $ 90.4k
Duncan William Budge	Senior Independent Non-Executive Director	7.5yrs	US$82.71k	0.0081% $ 87.4k
Colin Bond	Independent Non-Executive Director	7.4yrs	US$90.77k	0.0081% $ 87.4k
Stephanie Leouzon	Independent Non-Executive Director	5.3yrs	US$83.03k	no data
Sapna Shah	Independent Non-Executive Director	1.1yrs	US$64.02k	0.0051% $ 54.7k

6.3yrs

Average Tenure

62yo

Average Age

Experienced Board: BPCR's board of directors are considered experienced (6.3 years average tenure).

BioPharma Credit Management

Management criteria checks 1/4

Key information

Recent management updates

BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024

BioPharma Credit PLC, Annual General Meeting, Jun 09, 2022

BioPharma Credit PLC Announces Resignation of Jeremy William Sillem from the Board

Recent updates

BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024

Dividend of US$0.018 announced

Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024

BioPharma Credit PLC to Report Fiscal Year 2023 Results on Mar 27, 2024

BioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024

Sentiment Still Eluding BioPharma Credit PLC (LON:BPCR)

Biopharma Credit plc Declares Special Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024

BioPharma Credit PLC Provides Dividend Guidance for the Full Year Ending December 31, 2023

BioPharma Credit PLC to Report Q2, 2023 Results on Sep 27, 2023

BioPharma Credit (LON:BPCR) Is Due To Pay A Dividend Of $0.0175

BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2023, Payable on 15 September 2023

BioPharma Credit PLC Announces Special Dividend in Respect of the Financial Period Ended 5 October 2022, Payable on 18 November 2022

BioPharma Credit PLC to Report First Half, 2022 Results on Sep 14, 2022

BioPharma Credit (LON:BPCR) Has Announced A Dividend Of $0.0175

BioPharma Credit PLC Declares an Interim Dividend in Respect of the Financial Period Ending 30 June 2022, Payable on 23 September 2022

BioPharma Credit PLC, Annual General Meeting, Jun 09, 2022

BioPharma Credit PLC Declares Interim Dividend for the Financial Period Ended March 31, 2022, Payable on May 31, 2022; Provides Annual Dividend Guidance

BioPharma Credit plc Declares Interim Dividend for the Financial Period Ending 31 December 2021, Payable on 31 March 2022

Upcoming dividend of US$0.017 per share

BioPharma Credit PLC Declares Interim Dividend for the Financial Period Ended 31 March 2021 , Payable on 30 June 2021

BioPharma Credit PLC Approves Special Dividend, Payable on 16 April 2021

Biopharma Credit plc Declares an Interim Dividend in Respect of the Financial Period Ended December 31, 2020, Payable on March 31, 2021

New 90-day low: US$0.96

BioPharma Credit PLC to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: US$0.98

New 90-day low: US$0.99

BioPharma Credit PLC Announces Resignation of Jeremy William Sillem from the Board

New 90-day high - US$1.03

BioPharma Credit PLC to Report First Half, 2020 Results on Sep 16, 2020

An unknown buyer acquired BioPharma Credit PLC (LSE:BPCR) from Invesco Ltd. (NYSE:IVZ).

CEO

Board Members

Average Tenure

Average Age